We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 31

Report suggests Europe could become marine biotech leader by 2020
  • Shook Hardy & Bacon LLP
  • European Union
  • January 13 2011

The Marine Board of the European Science Foundation has released a report that suggests Europe could become a global leader in marine biotechnology by 2020, particularly by cultivating microalgae for fuel


EU trade group issues voluntary code for disclosures by pharma companies
  • Shook Hardy & Bacon LLP
  • European Union
  • July 11 2013

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has issued a "Code on Disclosure of Transfers of Value from


European markets less than enthusiastic over biosimilars
  • Shook Hardy & Bacon LLP
  • European Union, USA
  • December 12 2013

While Europe has had a regulatory approval pathway for biosimilar drug products for some years, their use reportedly remains anemic. Physicians are


EU Court of Justice Advocate General issues ruling on Stem Cell patentability
  • Shook Hardy & Bacon LLP
  • European Union, United Kingdom
  • August 7 2014

In a non-binding ruling, Advocate General Cruz Villalón of the EU Court of Justice has determined that unfertilized human ova whose division


European Parliament approves second medicines R&D initiative
  • Shook Hardy & Bacon LLP
  • European Union
  • May 1 2014

With opposition from the Green group, the European Parliament has apparently approved the second Innovative Medicines Initiative (IMI2), a 3


EU agency will reinstate Ranbaxy’s GMP certificate
  • Shook Hardy & Bacon LLP
  • European Union, India
  • June 12 2014

The European Medicines Agency (EMA) has reportedly concluded its investigation of alleged non-compliance with good manufacturing practice (GMP) at


Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • USA, Australia, Canada, European Union, United Kingdom
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies


April vote scheduled before EU Parliament on clinical trial data accessibility
  • Shook Hardy & Bacon LLP
  • European Union
  • March 20 2014

The European Parliament has postponed until April 2, 2014, debate on amended draft legislation (20120192 (COD)) that would require phar- maceutical


EU medical device manufacturers address plan to change regulatory directives
  • Shook Hardy & Bacon LLP
  • European Union
  • February 8 2013

Eucomed, an organization that represents the interests of the European medical device industry, has issued a position paper that assesses a number of


EU adds pharmaceuticals to water pollution watch list
  • Shook Hardy & Bacon LLP
  • European Union
  • July 11 2013

The European Commission (EC) has added 12 new substances to the European Union's (EU's) priority list of chemicals known to pose a risk to the safety